Illingworth Research Group (Spain) Sociedad Limitada, commonly referred to as Illingworth Research, is a prominent clinical research organisation headquartered in Spain. Established in 2010, the company has rapidly expanded its operational footprint across Europe, providing comprehensive services in the pharmaceutical and biotechnology sectors. Specialising in clinical trial management, patient recruitment, and regulatory affairs, Illingworth Research distinguishes itself through its innovative approach and commitment to quality. The firm has achieved significant milestones, including successful collaborations with leading pharmaceutical companies, which have solidified its position in the competitive landscape of clinical research. With a focus on enhancing patient engagement and streamlining trial processes, Illingworth Research continues to be a trusted partner for organisations seeking to advance their clinical development programmes. Its dedication to excellence and strategic growth has earned it a notable reputation within the industry.
How does Illingworth Research Group (Spain) Sociedad Limatada's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Illingworth Research Group (Spain) Sociedad Limatada's score of 48 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Illingworth Research Group (Spain) Sociedad Limatada currently does not report any specific carbon emissions data, as there are no available figures for kg CO2e emissions. The organisation is a current subsidiary of Syneos Health, Inc., and therefore, any climate commitments or emissions data may be inherited from this parent company. As a subsidiary, Illingworth Research Group aligns with the climate initiatives and targets set by Syneos Health, Inc. However, specific reduction targets or achievements for Illingworth Research Group are not detailed. The absence of documented reduction initiatives or climate pledges indicates that the company may still be in the process of establishing its own distinct climate strategy. Given the lack of direct emissions data and reduction commitments, it is essential for Illingworth Research Group to develop and communicate its climate action plans in line with industry standards to enhance transparency and accountability in its environmental impact.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 16,298,000 | 00,000,000 |
| Scope 2 | 9,704,000 | 0,000,000 |
| Scope 3 | 261,804,000 | 000,000,000 |
Illingworth Research Group (Spain) Sociedad Limatada's Scope 3 emissions, which decreased by 14% last year and decreased by approximately 14% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Illingworth Research Group (Spain) Sociedad Limatada has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.